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Food allergyThe purpose of this review is to discuss the role of mast cells in allergic inﬂammation. We have focused on
inﬂammation associated with allergic asthma and food allergy. Mast cells are ‘ﬁrst line of defense’ innate/
adaptive immune cells and are widely distributed in tissues in surfaces exposed to the environment.
Especially in allergic settings mast cells are extensively studied, as they can be activated to release a wide
range of mediators by allergen-IgE speciﬁc triggers. In addition, in allergic inﬂammation mast cells can also be
activated non-allergic triggers. Recent studies revealed that mast cells, besides the classical role of pro-
inﬂammatory effector cell, have also emerged as modulators of allergic sensitization and down-regulators of
allergic inﬂammation. Therefore, mast cells can be regarded as ‘Ying Yan’ modulators in allergic responses in
intestinal tract and airways. This article is part of a Special Issue entitled: Mast Cells in Inﬂammation.ells in Inﬂammation.
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Over the past decades the prevalence of allergic diseases, such as
asthma and food allergy, has increased dramatically. Allergic diseases
arise as a result of unwanted and exaggerated immune responses to
harmless proteins, also called allergens. A certain percentage of the
population experiences adverse immunological reactions to these
allergens that in non-allergic individuals only induce tolerance. This
failure of tolerance is believed to result in the induction of an active
immune response to allergens. One of the ﬁrst events in the
pathogenesis of allergy is capture and presentation of the allergen
by antigen presenting cells at mucosal sites in the airways or intestinal
tract and in draining lymph nodes, respectively. This will lead to the
development of a large population of antigen-speciﬁc T helper 2 cells
[1]. Activated allergen-speciﬁc T cells are found in the circulation of
allergic patients. These T helper 2 cells, once encountering the
allergen, will in turn activate B cells via the release of cytokines such
as interleukin 4 (IL4) and IL13 critical for the development of plasma
cells that will start the production of allergen speciﬁc immunoglob-
ulin E (IgE) as well as IgG [1–3]. These IgEs will bind to their receptor
FcεRI on basophils and extravascularly to mast cells. Allergen-induced
cross linking of the IgE bound FcεRI results in the activation of mast
cells. The release of mast cell derived pre-stored vasoactive amines,such as histamine and serotonin, and cytokines, such as tumor
necrosis factor α (TNFα), as well as produced cytokines and
arachidonic acidmetabolites, such as leukotrienes and prostaglandins.
IL4, IL9 and IL13 will further enhance the propagation of the
production of IgE and allergic inﬂammation in general. IL-5 and
granulocyte-macrophage colony-stimulating factor (GM CSF) are also
produced and are important for growth and differentiation of
eosinophils. Eosinophils are immune effector cells that can leave the
circulation through the interactions of adhesion molecules due to
chemo-attractants and migrate to the site of inﬂammation (For a
review see Ref. [3]).
Mast cells play a critical role in allergy and this makes them
attractive candidates for targeting allergic diseases. This review will
focus on the central role of mast cells in inﬂammation associated with
allergy, speciﬁcally in (allergic) asthma and food allergy.
2. Allergic asthma
Asthma represents a chronic inﬂammatory airway disease char-
acterized by episodes of reversible airway narrowing, bronchial
hyperresponsiveness and chronic pulmonary inﬂammation. Asthma
can be classiﬁed either according to frequency of symptoms (clinical)
or according to triggers causing the airway symptoms. Clinical
classiﬁcation of asthma severity consists of four types [4]. Intermit-
tent; patients suffer less than once a week from symptoms having a
forced expiratory volume in 1 s (FEV1) of more than 80% predicted.
Mild: patients suffer more than once per week, but less than once per
day from symptoms having a FEV1 of more than 80% predicted.
Moderate persistent: patients suffer daily from symptoms having a
FEV1 of 60–80% predicted. Severe persistent: patients suffer daily
94 A.D. Kraneveld et al. / Biochimica et Biophysica Acta 1822 (2012) 93–99from symptoms associated with nighttime symptoms and having a
FEV1 less than 60% predicted [5].
Asthma may also be classiﬁed as atopic, where symptoms are
induced by allergens or non-atopic where symptoms are induced by
non-speciﬁc triggers. Workplace exposures are the world's most
common cause of this so-called occupational asthma and 15–23% of
new-onset asthma cases in adults are work-related [6]. During
remission, patients suffer from symptoms such as nighttime coughing
and shortness of breath when exercising [7,8]. Exacerbation of the
disease consists of an acute asthma attack. During an asthma attack
patients are short of breath, suffer from chest tightness and have a
rapid heart rate (tachycardia) and wheezing can occur [7,8]. In the
pathology of asthma, the inﬂammation in the airways is characterized
by several inﬂammatory cells such as eosinophils, B lymphocytes and
T-lymphocytes, however, the role of mast cells is undisputed (see
Section 4).
More than 300 million people worldwide are diagnosed with
asthma. Developed and westernized countries have higher asthma
prevalence [9,10]. The prevalence of asthma has been increasing since
the 1980s, particularly in children and young adults. To date, asthma is
the most common chronic disease in children. Asthma is associated
with a western-life style and this has been shown clearly for example
by the rapid increase in the prevalence of asthma in children who
have beenmigrated from developing countries to developed countries
[11]. Four reasons could be involved in the increase of prevalence of
asthma associated with life style [12]. First, exposure to house dust
mite (major allergen in asthma) has increased due tomodern housing
and more time indoor. Secondly, exposure to a wide range of
microorganisms has changed because of improved hygiene and
wide spread antibiotic used. Thirdly, the prevalence of obesity has
increased in children. Last but not least, changes of the western diet
(decline of fresh vegetables, raw materials).
Classically, asthma has been regarded as a bronchoconstrictive
disease and is predominantly treatedwith bronchodilators, such as β2
agonists [13]. Currently, the chronic inﬂammatory process is the
target of treatment with inhaled corticosteroids. For the management
of asthma, patients take regularly inhaled corticosteroids with or
without long acting β2 agonists. However, 50% of the patients are
poorly controlled and there is still a need for new therapies. Blocking
the synthesis or receptor for a single mediator (such as lipid
mediators) involved in asthma seems unlikely to be very effective.
Anti-leukotrienes that block cysteinyl leukotriene receptor 1 (CysLt1),
are currently used in therapy, but these drugs are less effective than
inhaled corticosteroids [13]. In addition, leukotriene B4 (LTB4)
receptor antagonists had shown no effect in mild asthma [14].
Compounds targeting another arachidonic metabolite and its recep-
tor, prostaglandin D2, are now in clinical development for asthma.
Since cytokines play a crucial role in orchestrating chronic inﬂam-
mation, they have become important targets for asthma treatments.
However, over 50 cytokines have been implicated in asthma and
several cytokines and chemokines (IL4, IL5, IL13, TNFα, C-C
chemokine receptor type 3(CCR3)) blocking antibodies are now in
clinical development but clinical studies in asthmatic patients have
been disappointing [13]. Antibodies blocking IgE are only used in the
treatment of patients with severe asthma, due to high cost of
treatment and the unclear mechanism of clinical efﬁcacy (for a
review see Ref. [15]). The most promising anti-inﬂammatory therapy
is by the use of phosphodiesterase (PDE)4 inhibitors targeting T cells,
eosinophils, smooth muscle cells and epithelial cells. Roﬂumilast, an
oral PDE4 inhibitor, demonstrated inhibitory effects on allergen-
induced responses in asthma similar to low doses of inhaled
corticosteroids [16]. A different approach is speciﬁc immune therapy,
whereby asthmatic patients are exposed in a controlled way to
allergens or allergen-peptides, (either subcutaneously or sublin-
gually) to induce tolerance and desensitization. Some efﬁcacy by
this approach has been demonstrated, however, longer studies andcomparison with inhaled corticosteroids are needed to determine
efﬁcacy [13].
Targeting mast cells in allergic asthma is directed toward mast cell
sensitization, stabilization and their mediators released. Interestingly,
besides acting as a smooth muscle relaxant, β2 receptor antagonists
have been shown to stabilize mast cells [17,18]. Other mast cell
stabilizers, such as nedocromil and cromoglycate have only modest
effects in allergic asthma [19,20, for a review see Ref. 18]. Today, mast
cell stabilizers are not used in therapy.
To targeting mast cell sensitization the above mentioned anti-IgE-
antibody therapy can be regarded. The humanized anti-IgE-antibody,
omalizumab, did not show expected results and are only recom-
mended to use in difﬁcult-to-treat asthma [21–23, for a review see
Ref. [24]].
As described above, several compounds have been developed to
target mast cell mediators such as leukotrienes, prostaglandins and
cytokines, however, none of these compounds can beat the
corticosteroids.3. Food allergy
Food allergy is a growing problem inWestern Europe and the USA.
Intolerance or hypersensitivity reactions toward food or food
additives can result in adverse reactions after ingestion of a particular
food (for a review see Ref. [25]). Food hypersensitivity reactions
develop in genetically predisposed individuals associated with failure
in the development or breaking down of tolerance. Clinical symptoms
may involve dermatitis, respiratory distress and gastrointestinal
symptoms such as nausea, diarrhea and stomachache and can even
lead to a systemic anaphylactic reaction [26]. Food allergy, in contrast
to food intolerance, is immunological hypersensitivity reactionmostly
due to an inappropriate IgE- or non-IgE-mediated immune response.
IgE-mediated food allergy accounts for the majority of food allergic
reactions [26].
Typical foods accounting for food allergy are: cow milk, egg,
peanut, tree nuts, soy, wheat, shell ﬁsh and ﬁsh proteins [27]. The
prevalence of food allergy is the greatest during the ﬁrst years of life
where it affects around 8% of infants younger than 3 years of age [28].
Uncontrolled penetration of antigens through the not yet fully
developed mucosal epithelial barrier of the intestinal tract might
play a role in the increased prevalence during early life [27]. In this age
group cow milk allergy is the most common type of food allergy.
About 80% of these children develop clinical tolerance at the age of 5,
however, this group is at risk to develop allergic asthma at a later age
[27–29]. In adults, peanut hypersensitivity is the most common,
severe and dangerous food allergy [30,31]. Peanut allergy remains for
life and the prevalence rates exceed 1%.
Allergic reactions to food proteins can also occur independent of
IgE. To date the mechanisms underlying these reactions are not clear.
It has been suggested that T cells play a role in the immunopathogen-
esis as in cell-mediated or delayed type hypersensitivity reac-
tions [32]. Studies performed in our group suggest the involvement
of immunoglobulin free light chains (IgLC) in cowmilk allergy [33,34].
The only remedy in food allergy is strict avoidance of allergic food
components determined after a skin prick test. In several clinical trials
treatments with humanized recombinant anti-IgE antibodies have
shown to increase the threshold of sensitivity to peanut allergens [35].
However, in order to cure food allergy, re-education of the intestinal
immune system is necessary to establish oral tolerance. This can be
realized by performing allergen-speciﬁc immunotherapy. Recent
reports have demonstrated partial success with oral immunotherapy
in the treatment of food allergy [36–38]. Other strategies with
immuno-modulating dietary interventions, such as pre- and probio-
tics, are currently under research in preclinical and clinical studies
[39–41].
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The role of mast cells in allergic inﬂammation has extensively been
studied [42,43]. Triggering of mast cells and subsequent release of
pre-stored mediators play an important role in the immediate phase
of the allergic reaction resulting in vasodilatation, edema formation
and/or bronchoconstriction. Through the production and release of
chemotactic and other pro-inﬂammatory cytokines from mast cells,
other non-speciﬁc (eosinophils) and allergen-speciﬁc (T cells)
inﬂammatory cells inﬁltrate and get activated resulting in the late
phase response.
Basophils share several characteristics withmast cells and represent
less than1%of peripheral blood leukocytes. Theyhavebeen ignored for a
long time and were often considered to play a minor role in allergic
reactions. However, now it is widely acknowledged that basophils like
mast cells respond to IgE-dependent stimuli and are involved in the
onset, the effector phase and exacerbations of allergic (T helper 2 cell-
mediated) responses. Basophils are often recruited to the site of allergic
inﬂammation and release histamine, leukotrienes C4 and T helper 2
cytokines and play a role in T helper 2 cell differentiation. In addition,
they contribute to immunoglobulin synthesis and can present antigens
to T helper cells. [For reviews see Refs. [44,45]]. The role of basophils in
allergy is beyond the scope of this review.
As mentioned before, there is a prominent role for mast cells in
allergic asthma. In the healthy human lung the major mast cell type is
tryptase positive, whereas 20% is double tryptase and chymase
positive [46]. Tryptase positive mast cells are predominantly found
at mucosal sites. In contrast, tryptase and chymase positive mast cells
are located in the skin and submucosa, protected from external
triggers [47]. It is generally believed that the microenvironment is
important for the phenotype of mast cells and changes in this
microenvironment (for example during allergic inﬂammation) can
induce changes in mast cell type. The two mast cell phenotypes
functionally differ: tryptase and chymase positive mast cells seem to
be more responsive to allergic triggers when compared to only
tryptase positive mast cells. Recently it was demonstrated that
increasing asthma severity is associated with an enhanced shift
toward tryptase and chymase positive mast cells in airway mucosa
[48]. In addition, it was suggested that these mast cells contribute to
the increased level of PGD2 in bronchoalveolar lavage ﬂuid of severe
asthmatics.
The role of mast cells in food allergy is indicated by high levels of
histamine, TNFα, IL5 and tryptase in serum, intestinal lavage ﬂuid and
stool samples of patients suffering from food allergy [49,50].
Impairment of intestinal barrier function is of importance in food
allergy and it has been shown that inﬂammation enhances intestinal
mucosal permeability bymast cell-dependentmechanisms [51,52]. As
a result intestinal mast cells can contribute to an ongoing inﬂamma-
tion due to enhanced inﬂux of potential allergens and harmful
microbes into the intestinal tissue [50]. Indeed, in vitro studies using
epithelial cells, have shown that human chymase can induce
increased intestinal permeability [53]. Mast cell degranulation in the
intestinal mucosa has been demonstrated in food allergic individuals
[54]. Furthermore, it has been shown that IgE-stimulated mast cells
trigger enteric nerves resulting in pain and diarrhea [52,55]. The
development of oral antigen-induced diarrhea in mice is associated
with a marked intestinal mucosal mast cell degranulation.
As described for the human lung, tryptase and chymase positive
mast cells are found in the submucosa of the intestinal tract, whereas
tryptase positive mast cells are located in the mucosa [56]. To our
knowledge, not much is known about the mast cell phenotype
involved in food allergic patients. Based on the direct effects of human
chymase on epithelial integrity, however, it is tempting to speculate
that the tryptase and chymase positive mast cell population is
responsible for the food allergy symptoms such as decreased barrier
function and diarrhea.The role of mast cells in the pathogenesis of allergic asthma and
food allergy has been studied in different animal models, especially
using genetic mast cell deﬁcient mice (WBB6F1-Kit W/Wv or C57BL/6-
Kit W-sh/W-sh) and mast cell-reconstituted mice [57–60]. In these
studies, mast cells have been shown to either directly or indirectly
enhance the magnitude of several features of allergic asthma: airway
hyperresponsiveness, inﬁltration of leukocytes, mucus production
and tissue remodeling. However, in experimental setting where high
doses of antigen and adjuvants were used to induce allergic asthma no
contribution of mast cells was detected.
Mice deﬁcient in mast cell deﬁcient or mast cell chymase show
enhanced intestinal barrier function [53]. To our knowledge only one
study in mast cell deﬁcient and reconstituted mice is performed in a
murine model for food allergy, where it was shown that mast cells are
important in promoting the development of peanut-induced intesti-
nal responses [57]. All studies in mast cell deﬁcient mice do not
exactly pinpoint where mast cells play a role in the pathogenesis of
allergic inﬂammation. Therefore, below we will describe the current
knowledge of the role of mast cells in the sensitization and effector
phase of allergic inﬂammation as well as their possible role in
suppression of the allergic inﬂammation.
4.1. Involvement of mast cells in sensitization to allergens
It has been hypothesized that mast cells can be involved in the
process of sensitization to allergens because of their role as regulators
of epithelial barrier integrity. In the gastrointestinal tract, it has been
demonstrated that non-speciﬁc mast cell activation (for example
chronic stress) can lead to an increase epithelial permeability leading
to a higher exposure to allergens and thus induction of sensitization to
food allergens [61,62]. In addition, studies in mast cell deﬁcient mice
have shown thatmast cells are important in the recruitmentof dendritic
cells, in the induction of major histocompatibility complex-I (MHC-I)
dependent T cell priming and proliferation of CD4+ and CD8+ T cells
[63]. Mast cell-derived TNFα induces themigration of T cells to draining
lymphnodes at sites of inﬂammation demonstrating a role formast cells
in the processing of environmental allergens [64]. Furthermore, mast
cells are proposed to become antigen-presenting cells for T cells due to
factors from themicro-environment that induce the expression of MHC
class II on mast cells [65]. For instance the TLR4 ligand, lipopolysaccha-
ride, induces an increased number of MCHII-expressing mast cells in
lymph nodes ofmice [65]. Mast cells are able to produce and release IL4
and IL13. These cytokines promote Ig class switching and IgE
production. Finally, it is shown that allergens can be stored in lysosomes
of mast cells after ﬁrst being internalized by IgE-FcεRI-mediated
phagocytosis [66]. Noted should be that these antigen-containing
mast cells can activate antigen-speciﬁc T cells responses in vitro only
when they undergo apoptosis and are then ingested by antigen-
presenting cells [58]. Thus mast cells can drive further IgE production
and epitope spreading in allergic diseases.
4.2. The role of mast cells in the onset of allergic inﬂammation
Allergen-IgE dependent mast cell activation is widely regarded to
be the major initiator of the clinical signs and symptoms that are
demonstrated rapidly after exposure of small amounts of allergen to
an allergic individual. However, mast cells express many stimulatory
and inhibitory receptors. Allergen-speciﬁc mast cell activation can
occur via IgE, IgG1, IgG2a and IgG2b through the cross-linking of their
high afﬁnity IgE receptor , FcεRI, FcγRI (human), FcγRIIa (human/
mouse) or FcγRIIIa (mouse) receptors [67,68]. In addition, antigen-
speciﬁc mast cell degranulation can also be induced by cross-linking
of immunoglobulin free light chains IgLC [32]. This mechanism might
also be involved in asthma or food allergy, since blockage of IgLC was
effective in down regulating airway and skin hypersensitivity re-
actions in murine models of asthma and cow milk allergy [33,69].
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allergic setting. Activation of neuropeptide receptors, c-Kit, toll-like
receptors (TLRs), complement receptors or direct interaction with G-
proteins can also be involved in mast cell activation [67,70–74]. Of
interest are TLRs, since mast cells found in the submucosa and serosa
express greater levels of TLR2, TLR3, TLR4, TLR7 and TLR9 compared to
mucosal mast cells [75]. TLR2 and TLR4 ligands directly induce the
generation and release of inﬂammatory mediators from mast cells
[76,77]. In addition, in the context of allergic asthma, TLR ligands such as
lipopolysaccharide (TLR4 ligand) are suggested to synergize with the
crosslinkingof allergen-IgE-FcεRI to enhance allergic inﬂammation [78].
Furthermore, it has been demonstrated that commensal bacteria in the
intestinal tract via TLR signaling promote the migration of mast cells to
the intestine [79]. Similar functions have been reported for chemokine
receptors: CCR1 and CCR3 are involved in IgE-induced mast cell
activation and epithelial derived CXCR2 ligands are important in the
TLR-mediated mast cell recruitment to the intestinal tract [17,79].
Activated mast cells release their pre-stored mediators (vasoactive
amines, cytokines suchas TNFα, proteases, peptides suchasbradykinin)
via exocytose of their granules or via differential release of mediators
without degranulation, so-called piece meal degranulation [80]. The
pre-stored vasoactive amines, such as histamine and serotonin,mediate
mainly vascular effects associatedwith the inﬂammatory response such
as vasodilatation/constriction and changes in vascular permeability as
well as acute bronchoconstriction [80]. The acutely released proteases,
such as tryptase and chymase are involved in tissue damage and the
peptides (bradykinin, substance P, vasoactive intestinal peptide and
vascular endothelial growth factor (VEGF) are also involved in the acute
inﬂammation and pain perception [80].
Mast cell activation also leads to the ‘de novo’ synthesis and
release of lipid mediators and chemokines and cytokines. The newly
synthesized arachidonic acid metabolites such as LTB4 and LTC4,
platelet activating factor (PAF) and prostaglandin D2, cytokines,
among which IL1, IL4, IL5, IL6, IL9, IL13, interferon γ (IFNγ) and TNFα,
and chemokines are responsible for the late phase event during an
allergic inﬂammatory response: leukocyte migration, inﬁltration and
activation [73,74,80,81].suppression
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Fig. 1. The two faces of mast cells in allergic inﬂammation: inducer/activator and
suppressor. MHC: major histocompatibility complex; IL: interleukin; PAF: platelet
activating factor; FcεR: IgE receptor; FcγR: IgG receptor; IgLR: Ig light chain receptor;
TNFα: tumor necrosis factor α; NK receptor: neurokinin receptor; 5HT: serotonin; TLR:
toll like receptor; sens: sensitization phase. Adapted from Ref. [98].4.3. Mast cells as suppressors of allergic inﬂammation
Recently, attention has been drawn to the potential role of mast
cells in suppressing or breaking of allergic inﬂammation.
First, itwas demonstrated thatmast cell-derived proteases (such as
β-tryptase) can cleave IgE. Treatment with protamine (an inhibitor of
proteases) enhanced IgE-mediated allergic skin inﬂammation in man
[82]. Although not yet demonstrated in an allergic setting, it has been
shown that endogenous and exogenous peptides (endothelin-1,
neurotensin and snake venom) that induce mast cell activation are
also cleaved by mast cell proteases and thereby down-regulating the
peptide damaging effects [83–85]. In addition, mast cells have been
shown to have immunosuppressive functions followingUVB radiation,
mosquito bites or in peripheral tolerance to skin allocrafts [86–88].
Howmast cellsmediate these immunosuppressive effects remain to be
elucidated, but naturally arising regulatory T cells seem to be involved
[88]. IL9 derived from these regulatory T cells induces the recruitment
and activation of mast cells. In turn, mast cells can mediate this
immunomodulatory function in vivo by the production of IL10.
Recently, the role of naturally arising regulatory T cells in the induction
of oral tolerance to peanut allergens was challenged. Rezende and
coworkers [89] have demonstrated that adoptive transfer of naturally
arsing regulatory T cells from peanut tolerant mice did not induced
tolerance in recipient mice that were sensitized to peanut. They found
evidence that TGFβ-secreting regulatory T cellsmay play an important
role instead. However, in several clinical trials of allergen speciﬁc
immunotherapy in allergic subjects, the induction of tolerance seemsto be related to naturally arising regulatory T cells and IL10 producing
type 1 regulatory T cells [For a review see Ref. [90]].
IL10 derived from mast cells is important for the limitation of
chronic skin inﬂammation following contact hypersensitivity re-
sponses to the allergen-containing components of poison ivy [91]. The
pathways that link mast cells-IL10 to the observed changes remain to
be deﬁned and to be shown in an allergic setting.
Lastly,mast cells are equipped to sense the environment to decide to
become potentially suppressive in allergic inﬂammation. It has been
suggested that such action could be realized via sialic acid-binding
immunoglobulin-like lectin 8 (siglec-8) [92]. Siglecs are cell surface
receptors andmember of immunoglobulin super family (I-type lectins)
that recognize sugars [93]. Siglec-8 is highly similar in structure to CD33
and has two conserved immunoreceptor tyrosine-based inhibitory
motif (ITIMs)-like motifs in their cytoplasmic tails [94]. This suggests
that siglec-8 function as inhibitorymolecules. In vitro, siglec-8 promotes
the apoptosis of eosinophils and inhibits IgE-FcεRI-induced mast cell
mediator release [95,96]. Recently, Gao and coworkers have described
that polymorphisms of the siglec-8 gene are associated with the
susceptibility to asthma [97]. Further studies are required to validate
siglec-8 as useful target to inducemast cell-dependent down regulation
of allergic inﬂammation.
5. The two faces of mast cells in allergic inﬂammation: Ying Yan
concept
Mast cells are typically regarded as troublesome cells due to their
prominent role in IgE-dependent allergic hypersensitivity reactions
such as allergic asthma and food allergy. Further, it seems that mast
cells are also able to play an additional role in the ‘allergic’
sensitization-processes. Recent ﬁndings show that mast cell function-
ality is not only pro-inﬂammatory, but can on the contrary have
suppressive or immunomodulatory effects in allergic inﬂammation
(Fig. 1). The latter is mainly based on in vitro-studies and one should
keep inmind that these circumstances do not reﬂect the true nature of
mast cells in their micro-environment in intestinal wall or airways.
More evidence needs to be obtained from in vivo and human studies to
prove the immunomodulatory role of mast cells in allergic inﬂamma-
tion. In Chinese philosophy, the concept of yin yang is used to describe
inflammation
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suppression
re
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Fig. 2. Yin Yang concept for mast cells. The suppressor and activator roles of mast cells in
allergic inﬂammation are seemingly contrary.While mast cells play an important activator
role in allergic inﬂammation, Mother Nature has created a down regulating role for mast
cells as well. Only during allergic exacerbations there is an imbalance of these mast cell
functions resulting in the symptoms related to allergic asthma and food allergy. During
remission the balance is restored. Opposite roles formast cells in allergic inﬂammation thus
only exist in relation to each other. Thus mast cells follow the Yin Yang concept in allergy.
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dent in the natural world, and how they give rise to each other in turn.
May be we should regard the suppressor and activator roles of mast
cells in allergic inﬂammation as such. While inducing inﬂammation,
Mother Nature has created a down regulating role for mast cells as
well. Only during allergic exacerbations there is an imbalance of these
mast cell functions resulting in the symptoms related to allergic
asthma and food allergy. Opposite roles for mast cells in allergic
inﬂammation thus only exist in relation to each other (Fig. 2).
Still, the possible suppressor role of mast cell in allergic
inﬂammation and/or the possible role of mast cells in the develop-
ment of immunological tolerance, leads to the following questions:
1. How careful should we be in targeting mast cells in allergic
inﬂammation?
2. How can we manipulate speciﬁc mast cell suppressor functions
therapeutically?
A better understanding of mast cell biology will give us new
insights for improving strategies to treat allergic inﬂammation
associated with asthma and food allergy.
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